CAR-T cell therapy for relapsed or refractory multiple myeloma or plasma cell leukemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with relapsed or refractory multiple myeloma or plasma cell leukemia.
- You have tried at least one prior treatment (for multiple myeloma, you must have tried a proteasome inhibitor, an IMiD, and a CD38 antibody, and your cancer must not have responded to the last treatment).
- You have measurable disease (cancer that can be seen on tests).
- You are generally healthy enough to undergo the treatment, with good organ function and an ECOG performance status of 0 or 1.
- You are willing to use effective contraception for at least 12 months after the treatment if you are of childbearing age or a man.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.